Compare CVE & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CVE | EW |
|---|---|---|
| Founded | 2009 | 1958 |
| Country | Canada | United States |
| Employees | 7211 | N/A |
| Industry | Oil & Gas Production | Industrial Specialties |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.4B | 50.2B |
| IPO Year | N/A | 1999 |
| Metric | CVE | EW |
|---|---|---|
| Price | $26.84 | $79.42 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 21 |
| Target Price | $30.50 | ★ $96.47 |
| AVG Volume (30 Days) | ★ 16.1M | 4.0M |
| Earning Date | 05-07-2026 | 04-22-2026 |
| Dividend Yield | ★ 2.25% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.83 |
| Revenue | N/A | ★ $6,067,600,000.00 |
| Revenue This Year | N/A | $13.39 |
| Revenue Next Year | $5.69 | $9.78 |
| P/E Ratio | ★ $18.07 | $44.96 |
| Revenue Growth | N/A | ★ 11.55 |
| 52 Week Low | $10.23 | $65.94 |
| 52 Week High | $26.37 | $87.89 |
| Indicator | CVE | EW |
|---|---|---|
| Relative Strength Index (RSI) | 78.38 | 39.20 |
| Support Level | $16.27 | $75.59 |
| Resistance Level | N/A | $82.64 |
| Average True Range (ATR) | 0.73 | 2.10 |
| MACD | 0.19 | -0.43 |
| Stochastic Oscillator | 98.41 | 10.17 |
Cenovus Energy Inc is a Canadian integrated energy group. The group's upstream operations include oil sands projects in northern Alberta; thermal and conventional crude oil, natural gas, and natural gas liquids (NGLs) projects across Western Canada; crude oil production offshore Newfoundland and Labrador; and natural gas and NGLs production offshore China and Indonesia. Its downstream operations include upgrading and refining operations in Canada and the U.S., and commercial fuel operations across Canada. The group's reportable segments are: Oil Sands, Conventional, Offshore, Canadian Refining, U.S Refining, and Corporate and Eliminations. Maximum revenue is generated from its Oil Sands segment. Geographically, the group derives maximum revenue from the U.S., followed by Canada and China.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.